• Nasodine® Throat Spray launched in first international market - Singapore
• Throat spray complements Nasodine® Nasal Spray, providing comprehensive nasal and oral solution
• Plans to launch Nasodine Throat Spray in Fiji and USA during 2026, and other markets in the future

Firebrick Pharma Ltd (ASX:FRE) has announced the launch of its first new product, Nasodine® Throat Spray, in Singapore. The throat spray is a 1% povidone-iodine solution designed for oral use and is considered a valuable complement to the company's existing Nasodine® Nasal Spray. The new throat spray provides a compact, easy-to-use and pleasant tasting solution for sore throats, which are often the first sign of the common cold. Nasodine Throat Spray is being launched in Singapore by the company's exclusive licensing partner, Innorini Life Sciences. For the first six months, the focus will be on hospitals and healthcare professionals, after which the product will be made available to the retail channel. Firebrick also expects to see the Nasodine Throat Spray introduced in Fiji and the USA during 2026, and in other markets in the future where Nasodine Nasal Spray is approved. The company is aiming to build a valuable Nasodine franchise based on multiple products across multiple markets.

Firebrick Pharma plans to introduce the Nasodine Throat Spray in Fiji and the USA during 2026, and in other markets in the future where Nasodine Nasal Spray is approved. The company is also planning to launch other new Nasodine products in existing markets in 2026.